Clinical Assessment: 35M with Postprandial Spasmodic Abdominal Pain + Deranged LFTs

Interpreting the Biochemical Pattern

Differential Diagnosis (Priority Order)

1. Hereditary Spherocytosis or Hemolytic Anemia + Biliary Colic (Pigment Stones)

• Most likely unifying diagnosis: Chronic hemolysis leads to excess bilirubin production, causing pigment (bilirubin) gallstones
• Pigment stones cause postprandial spasmodic biliary colic
• Hemolysis explains the predominantly indirect hyperbilirubinemia
• The mild transaminase elevation can occur from concurrent hepatocyte irritation, or from the inflammatory history

2. Gilbert Syndrome + Concurrent Hepatic Inflammation

• Gilbert's affects 3-5% of the population, more common in males (Henry's Clinical Diagnosis, p.1166)
• UGT1A1 promoter mutation causes 70% reduction in conjugation capacity
• Total bilirubin typically 2-3 mg/dL; rises with fasting, stress, illness
• Does NOT cause abdominal pain by itself - the pain needs a separate explanation
• The mildly elevated AST/ALT here argues against pure Gilbert's (which has normal transaminases)

3. Mesalamine (Mesalazine) Hepatotoxicity

• This is a clinically important consideration given the history
• Published case report (PMID: 35048663, Eur J Gastroenterol Hepatol 2021): mesalazine can cause hepatotoxicity - termed "the forgotten drug" as a hepatotoxic agent in IBD
• The drug may have been stopped (colitis resolved), but residual hepatic inflammation or an unrecognized ongoing subclinical exposure could explain the transaminase elevation
• Onset can be delayed or persistent after discontinuation

4. Concurrent IBD-related Extraintestinal Manifestation (Primary Sclerosing Cholangitis - PSC)

• IBD (especially ulcerative colitis) is the strongest known risk factor for PSC
• PSC typically causes elevated ALP and GGT with cholestatic pattern, but early PSC can present with mildly elevated transaminases
• Less likely here given the predominantly indirect bilirubin pattern, but must be excluded

5. Viral Hepatitis with Coincident Indirect Hyperbilirubinemia

• Acute hepatitis A, B, or E can cause abdominal pain + elevated AST/ALT
• Gilbert's syndrome (pre-existing) can exaggerate bilirubin elevation during any acute illness

Further Investigation Plan

Tier 1 - Mandatory First Line

Tier 2 - After Tier 1 Results

Tier 3 - Specialized (Directed by Prior Results)

Treatment Planning

Immediate / Supportive

• Avoid fasting - in Gilbert's syndrome, fasting worsens indirect hyperbilirubinemia
• Stop any hepatotoxic drugs - if mesalamine was recently taken or is still being used, consider stopping and monitoring LFTs; rechallenging later can confirm DILI (do NOT rechallenge if severe reaction)
• Adequate hydration - especially if hemolysis suspected
• Avoid alcohol completely while LFTs are deranged

Directed Treatment (Based on Diagnosis)

• Treat the underlying hemolysis (immunosuppression for autoimmune hemolysis; avoid triggers for G6PD/hereditary spherocytosis)
• Laparoscopic cholecystectomy for symptomatic pigment gallstones causing biliary colic
• Ursodeoxycholic acid is less effective for pigment stones than cholesterol stones

• Reassurance - benign condition, no progressive liver damage, no treatment required
• Counsel about triggers: fasting, illness, dehydration, strenuous exercise
• Note: Gilbert's patients may have increased risk of jaundice with certain drugs (e.g., irinotecan, atazanavir) - relevant for IBD treatment planning

• Discontinue mesalamine
• Monitor LFTs every 2-4 weeks
• If IBD recurs, consider alternative: sulfasalazine (though cross-hepatotoxicity possible), budesonide, or biologics (infliximab, vedolizumab)
• Recovery is expected within weeks of stopping the drug

• Hepatitis A/E: supportive care, self-limiting
• Hepatitis B: assess viral load; antiviral treatment if indicated (tenofovir, entecavir)
• Hepatitis C: direct-acting antivirals (DAAs)

• Ursodeoxycholic acid (controversial in PSC - some guidelines no longer recommend high-dose)
• Endoscopic dilation of dominant strictures when symptomatic
• Screening for cholangiocarcinoma and colorectal cancer

• Prednisolone + azathioprine (standard induction + maintenance)

Summary Approach

CBC + Retic + LDH + Haptoglobin + Coombs
       ↓
Hemolysis confirmed?
  YES → Peripheral smear → Hereditary/Autoimmune cause → Treat + USG for pigment stones
  NO  → ALP/GGT + Viral screen
         ↓
     ALP/GGT elevated → MRCP → PSC/obstruction
     ALP/GGT normal, transaminases mild → Gilbert's + DILI (mesalamine) workup

• Harrison's Principles of Internal Medicine 22E (2025, McGraw Hill) - Table 348-1: Liver Test Patterns in Hepatobiliary Disorders
• Henry's Clinical Diagnosis and Management by Laboratory Methods - Derangements of Bilirubin Metabolism, p.1163-1166
• Textbook of Family Medicine 9e - Bilirubin, p.221
• Garrido I et al. "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug." Eur J Gastroenterol Hepatol 2021. PMID: 35048663

Your Files Are Ready

1. Lecture Presentation (PowerPoint)

2. Student Assessment Handout (PDF)

What's Inside

PowerPoint (40 slides, ~60–75 minute lecture)

MCQ Handout (3-page PDF)

• Section A: 30 single-best-answer MCQs (1 mark each) covering anatomy, pathology, examination, staging, and treatment
• Section B: 8 short answer questions (4 marks each) – students answer any 5
• Total: 50 marks | 45-minute paper
• Full answer key with explanations on the last page (for examiner use)

Content Sources